Imunon, Inc. (IMNN) has reported promising results from its Phase 2 OVATION 2 Study concerning IMNN-001, an investigational IL-12 immunotherapy designed for advanced ovarian cancer treatment. This study evaluated the safety and effectiveness of IMNN-001 when combined with neoadjuvant and adjuvant chemotherapy (NACT), specifically paclitaxel and carboplatin, against the standard NACT regimen.
Participants receiving the IMNN-001 alongside standard NACT experienced an 11.1-month increase in survival compared to those on NACT alone. Additionally, the treatment with IMNN-001 led to improved surgical outcomes, enhanced progression-free survival, and was well-tolerated by patients.
Imunon is now planning an in-person meeting with the FDA at the conclusion of Phase 2 to discuss the forthcoming Phase 3 pivotal trial, anticipated to commence in the first quarter of next year.
Currently, Imunon's stock is experiencing a downturn, decreasing by 8.14 percent to $0.86 on the Nasdaq.
